Valuation: Alzinova AB

Market Cap 14Cr 1.46Cr 1.28Cr 1.18Cr 1.09Cr 2.07Cr 139.33Cr 2.1Cr 5.53Cr 68Cr 5.48Cr 5.36Cr 236.99Cr P/E 2026 *
-3.37x
P/E 2027 * -2.39x
Enterprise Value 13Cr 1.29Cr 1.13Cr 1.04Cr 96.59L 1.83Cr 123.52Cr 1.86Cr 4.9Cr 61Cr 4.86Cr 4.75Cr 210.1Cr EV / Sales 2026 *
3.99x
EV / Sales 2027 * -
Free-Float
82.23%
Yield 2026 *
-
Yield 2027 * -
1 day-5.49%
1 week+73.74%
Current month+73.39%
1 month+94.79%
3 months+45.76%
6 months+10.26%
Current year+3.74%
1 week 0.48
Extreme 0.48
1.61
1 month 0.44
Extreme 0.438
1.61
Current year 0.38
Extreme 0.382
1.61
1 year 0.38
Extreme 0.382
2.28
3 years 0.38
Extreme 0.382
4.62
5 years 0.38
Extreme 0.382
8.79
10 years 0.38
Extreme 0.382
44.9
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2024
Chief Operating Officer 54 17/08/2011
Director of Finance/CFO 57 27/03/2024
Director TitleAgeSince
Director/Board Member 61 01/09/2015
Director/Board Member 69 01/01/2018
Director/Board Member - 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-3.30%+73.74%-48.56%-74.06% 1.46Cr
+0.86%+2.44%+3.30%+11.28% 5.04TCr
-1.03%-0.76%+389.75%+592.96% 4.06TCr
+0.10%+1.83%+26.71%-4.42% 3.49TCr
-1.07%-3.09%+18.35%+55.76% 3.37TCr
-2.09%-1.98%+3.21%+33.56% 2.63TCr
-1.47%+1.03% - - 1.71TCr
-0.03%-5.47%+62.73%+120.92% 1.53TCr
-6.22%-28.11%+41.10%+43.13% 1.06TCr
+1.13%+0.35%+14.81%+22.23% 1.37TCr
Average -1.59%+5.06%+56.82%+89.04% 2.43TCr
Weighted average by Cap. -0.71%-0.60%+85.27%+132.46%

Financials

2026 *2027 *
Net sales 3.14Cr 32.45L 28.39L 26.18L 24.22L 45.97L 31Cr 46.74L 1.23Cr 15Cr 1.22Cr 1.19Cr 53Cr -
Net income -32L -3L -3L -3L -2L -5L -3.16Cr -5L -12.54L -1.55Cr -12.43L -12.17L -5.38Cr -5.04Cr -52.12L -45.59L -42.04L -38.9L -73.84L -50Cr -75.07L -1.97Cr -24Cr -1.96Cr -1.91Cr -85Cr
Net Debt -1.6Cr -16.56L -14.49L -13.36L -12.36L -23.46L -16Cr -23.86L -62.72L -7.76Cr -62.17L -60.83L -27Cr -1.9Cr -19.67L -17.2L -15.87L -14.68L -27.86L -19Cr -28.33L -74.48L -9.22Cr -73.83L -72.23L -32Cr
Logo Alzinova AB
Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.
Employees
7
Date Price Change Volume
10/26/10 SEK 0.8800 -3.30% 72,23,241
09/26/09 SEK 0.9100 -11.82% 1,47,41,167
08/26/08 SEK 1.032 -26.29% 7,61,53,518
07/26/07 SEK 1.400 +191.67% 9,70,09,916
06/26/06 SEK 0.4800 -3.03% 10,43,697

Annual profits - Rate of surprise